Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3RAKLES: Tucatinib and Trastuzumab in HER3-mutant Metastatic Breast Cancer
NCT07193394Phase 2Recruiting
- Sponsor
- Institut Curie
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in breast cancer, sponsored by Institut Curie. Started Jan 2026; status: recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07193394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193394.